This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, F. Articles by Holly, E. A. Search for Related Content PubMed PubMed Citation Articles by Wang, F. Articles by Holly, E. A.

Diabetes Mellitus and Pancreatic Cancer in a Population-Based Case-Control Study in the San Francisco Bay Area, California

¹ Department of Epidemiology and Biostatistics, School of Medicine, and ² Department of Medicine, Division of Gastroenterology, University of California San Francisco, San Francisco, California; and ³ Department of Health Research and Policy, School of Medicine, Stanford University, Stanford, California

Requests for reprints: Elizabeth A. Holly, Division of Cancer Epidemiology, Department of Epidemiology and Biostatistics, University of California San Francisco, Suite 280, 3333 California Street, San Francisco, CA 94118-1944. Phone: 415-476-3355; Fax: 415-563-4602. E-mail: elizabeth.holly{at}ucsf.edu

Background: Diabetes has been postulated to be both a risk factor and a consequence of pancreatic cancer, but the degree of risk and associated clinical factors remain unclear.

Methods: We conducted a population-based case-control study of pancreatic cancer in the San Francisco Bay Area between 1995 and 1999. Rapid case ascertainment through the Surveillance, Epidemiology and End Results registry for cases and random selection from the general population for controls were employed to identify study participants with no proxy interviews.

Results: Five hundred thirty-two cases and 1,701 controls were interviewed. Participants with pancreatic cancer were more likely to report a history of diabetes (13%) than were controls [9%; odds ratio (OR), 1.5; 95% confidence interval (95% CI), 1.1-2.1]. Compared with diabetics in the control group, diabetics in the case group had a shorter duration of diabetes (P = 0.0003) and a larger proportion of insulin users (P = 0.002). Risk for pancreatic cancer varied with duration of diabetes (OR, 2.4; 95% CI, 1.4-4.0 for 1-4 years; OR, 2.0; 95% CI, 1.2-3.4 for 5-9 years; and OR, 0.86; 95% CI, 0.52-1.4 for 10 years diabetes duration; P_trend = 0.004). Among diabetics, use of oral diabetes medication or insulin for 5 years was not associated with pancreatic cancer, but insulin use of <5 years was associated with a 6.8-fold risk for pancreatic cancer (95% CI, 3.7-12).

Conclusion: Recent-onset diabetes may be a complication or an early marker of pancreatic cancer. Diabetes of short duration with insulin use conferred a substantially elevated risk for pancreatic cancer and may reflect insulin resistance that is elicited by pancreatic cancer. (Cancer Epidemiol Biomarker Prev 2006;15(8):1458–63)

This article has been cited by other articles:

				M. M. Hassan, D. Li, A. S. El-Deeb, R. A. Wolff, M. L. Bondy, M. Davila, and J. L. Abbruzzese Association Between Hepatitis B Virus and Pancreatic Cancer J. Clin. Oncol., October 1, 2008; 26(28): 4557 - 4562. [Abstract] [Full Text] [PDF]

				E. J. Duell, P. M. Bracci, J. H. Moore, R. D. Burk, K. T. Kelsey, and E. A. Holly Detecting Pathway-Based Gene-Gene and Gene-Environment Interactions in Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1470 - 1479. [Abstract] [Full Text] [PDF]

				J. M. Chan, F. Wang, and E. A. Holly Whole Grains and Risk of Pancreatic Cancer in a Large Population-based Case-Control Study in the San Francisco Bay Area, California Am. J. Epidemiol., November 15, 2007; 166(10): 1174 - 1185. [Abstract] [Full Text] [PDF]